Table 5 Study 203 Mean (X) and Mean Change
(∆) from Baseline in HAMD Depressed Mood Item #1 |
||||||||||||||||||
LAST OBSERVATION CARRIED
FORWARD ANALYSIS |
||||||||||||||||||
Treatment Groups |
Treatment Week |
|||||||||||||||||
Baseline |
Wk 1 |
Wk 2 |
Wk 3 |
Wk 4 |
Wk 5 |
Wk 6 |
Wk 7 |
Wk 8 |
||||||||||
N |
X |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
|
BUP
SR 150 (L) |
120 |
2.8 |
11.3 |
-0.3 |
120 |
-0.7 |
120 |
-0.9 |
120 |
-1.0 |
120 |
-1.1 |
120 |
-1.2 |
120 |
-1.2 |
120 |
-1.2 |
BUP
SR 300 (II) |
113 |
2.9 |
113 |
-0.4 |
113 |
-0.6 |
113 |
-0.9 |
113 |
-0.1 |
113 |
-1.1 |
113 |
-1.2 |
113 |
-1.2 |
113 |
-1.3 |
Placebo
(P) |
117 |
2.9 |
116 |
-0.3 |
117 |
-0.6 |
117 |
-0.7 |
117 |
-0.8 |
117 |
-0.9 |
117 |
-0.9 |
117 |
-0.9 |
117 |
-1.0 |
2-sided p-values for
pairwise comparisons |
||||||||||||||||||
I.
vs. P |
>0.5 |
0.9 |
0.5 |
0.2 |
0.1 |
0.2 |
0.06 |
0.03 |
0.08 |
|||||||||
II
vs. P |
>0.5 |
0.2 |
1.0 |
0.1 |
0.2 |
0.2 |
0.06 |
0.08 |
0.04 |
|||||||||
OBSERVED CASES ANALYSIS |
||||||||||||||||||
Treatment Groups |
Treatment Week |
|||||||||||||||||
Baseline |
Wk 1 |
Wk 2 |
Wk 3 |
Wk 4 |
Wk 5 |
Wk 6 |
Wk 7 |
Wk 8 |
||||||||||
N |
X |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
N |
∆ |
|
BUP
SR 150 (L) |
120 |
2.8 |
113 |
-0.3 |
109 |
-0.7 |
98 |
-0.9 |
89 |
-1.2 |
83 |
-1.3 |
70 |
-1.5 |
67 |
-1.7 |
64 |
-1.7 |
BUP
SR 300 (II) |
113 |
2.9 |
113 |
-0.4 |
100 |
-0.6 |
98 |
-1.0 |
87 |
-1.1 |
77 |
-1.4 |
74 |
-1.6 |
69 |
-1.6 |
62 |
-1.9 |
Placebo
(P) |
117 |
2.9 |
116 |
-0.3 |
112 |
-0.6 |
102 |
-0.8 |
91 |
-1.0 |
75 |
-1.2 |
69 |
-1.4 |
64 |
-1.5 |
56 |
-1.6 |
2-sided p-values for
pairwise comparisons |
||||||||||||||||||
I.
vs. P |
>0.5 |
0.9 |
0.6 |
0.3 |
0.2 |
0.3 |
0.6 |
0.4 |
0.6 |
|||||||||
II
vs. P |
>0.5 |
0.2 |
1.0 |
0.1 |
0.2 |
0.2 |
0.5 |
0.6 |
0.3 |
Bupropion
Sustained-Release Clinical Review 51
Back a Page
Next Page
Back to Wellbutrin SRŪ NDA Index Page
Back to Main
Index